Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma

被引：1

作者：

Dreyling, Martin ^{[1
]}

Panayiotidis, Panayiotis ^{[2
]}

Follows, George A. ^{[3
]}

Mollica, Luigina ^{[4
]}

Nagler, Arnon ^{[5
]}

Ozcan, Muhit ^{[6
]}

Santoro, Armando ^{[7
]}

Stevens, Don ^{[8
]}

Trevarthen, David ^{[9
]}

Hiemeyer, Florian ^{[10
]}

Liu, Li ^{[11
]}

Garcia-Vargas, Jose ^{[11
]}

Childs, Barrett H. ^{[11
]}

Zinzani, Pier Luigi ^{[12
]}

机构：

[1] Univ Hosp LMU, Dept Med 3, Munich, Germany

[2] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece

[3] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England

[4] Maisonneuve Rosemont Hosp Res Ctr, Montreal, PQ, Canada

[5] Tel Aviv Univ, Chaim Sheba Med Ctr, Tel Hashomer, Israel

[6] Ankara Univ, Ankara, Turkey

[7] Humanitas Clin & Res Ctr, Rozzano, Italy

[8] Norton Canc Inst, Louisville, KY USA

[9] Comprehens Canc Care & Res Inst Colorado, Englewood, CO USA

[10] Bayer AG, Div Pharmaceut, Berlin, Germany

[11] Bayer HealthCare Pharmaceut Inc, Whippany, NJ USA

[12] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-121932

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1531

引用

页数：5

共 50 条

[21] Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase 2 Study
Wang, Michael
Rule, Simon
Zinzani, Pier Luigi
Goy, Andre H.
Casasnovas, Rene-Olivier
Smith, Stephen D.
Damaj, Gandhi Laurent
Doorduijn, Jeanette K.
Lamy, Thierry
Morschhauser, Franck
Panizo, Carlos
Shah, Bijal
Davies, Andrew
Eek, Richard
Dupuis, Jehan
Jacobsen, Eric
Kater, Arnon P.
Le Gouill, Steven
Oberic, Lucie
Robak, Tadeusz
Jain, Preetesh
Brock, Graham
Patel, Priti
Tao, Lin
Dlugosz-Danecka, Monika
BLOOD, 2020, 136
[22] Acalabrutinib Monotherapy in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results From a Phase 2 Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (04) : 6 - 7
[23] Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma
Kim, T. M.
Taszner, M.
Novelli, S.
Cho, S. -G
Villasboas, J. C.
Merli, M.
Jimenez-Ubieto, A.
Tessoulin, B.
Poon, L. M.
Tucker, D.
Walewski, J.
Yi, S.
Song, Y.
Chong, G.
Bachy, E.
Guidez, S.
Alonso, A.
Jagadeesh, D.
Zhang, W.
Magnano, L.
Iskierka-Jazdzewska, E.
Tani, M.
Shen, B.
Uppala, A.
Zhu, M.
Shariff, S.
Brouwer-Visser, J.
Chaudhry, A.
Mohamed, H.
Ambati, S.
Luminari, S.
ANNALS OF ONCOLOGY, 2024, 35 (11) : 1039 - 1047
[24] Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study
Song, Yuqin
Zhou, Keshu
Zou, Dehui
Zhou, Jianfeng
Hu, Jianda
Yang, Haiyan
Zhang, Huilai
Ji, Jie
Xu, Wei
Jin, Jie
Lv, Fangfang
Feng, Ru
Gao, Sujun
Guo, Haiyi
Zhou, Lei
Huang, Jane
Novotny, William
Kim, Pil
Yu, Yiling
Wu, Binghao
Zhu, Jun
BLOOD, 2022, 139 (21) : 3148 - 3158
[25] THE LONG-TERM EFFICACY AND SAFETY OF EVINACUMAB IN PATIENTS WITH REFRACTORY HYPERCHOLESTEROLEMIA
Rosenson, Robert S.
Burgess, Lesley J.
Ebenbichler, Christoph F.
Baum, Seth J.
Stroes, Erik S. G.
Ali, Shazia
Khilla, Nagwa
Pordy, Robert
Singh, Divya
Gaudet, Daniel
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 1099 - 1099
[26] LONG-TERM EFFICACY AND SAFETY OF CRIZOTINIB IN RELAPSED ALK POSITIVE LYMPHOMA PATIENTS: CLINICAL AND BIOLOGICAL CORRELATES
Farina, F.
Ceccon, M.
Mori, S.
Verga, L.
Borin, L. M.
Mologni, L.
Fontana, D.
Geeta, G.
Piazza, R.
Gambacorti-Passerini, C.
HAEMATOLOGICA, 2017, 102 : 221 - 222
[27] Evaluating ibrutinib for the treatment of relapsed/refractory marginal zone lymphoma
Cavalloni, Chiara
Varettoni, Marzia
Rattotti, Sara
Arcaini, Luca
EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (13) : 1643 - 1649
[28] Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib
Denlinger, Nathan M.
Epperla, Narendranath
William, Basem M.
CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 615 - 624
[29] Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204)
Phillips, Tycel
Avigdor, Abraham
Gurion, Ronit
Patti, Caterina
Corradini, Paolo
Tani, Monica
Mehta, Amitkumar
Lossos, Izidore S.
Lossos, Izidore S.
Zinzani, Pier Luigi Luigi
Thieblemont, Catherine
Jurczak, Wojciech
Zheng, Fred
Rappold, Erica
Zhao, Wanying
Johnson, Peter
BLOOD, 2021, 138
[30] Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma
Barzenje, Dlawer Abdulla
Holte, Harald
Fossa, Alexander
Ghanima, Waleed
Liestol, Knut
Delabie, Jan
Kolstad, Arne
LEUKEMIA & LYMPHOMA, 2017, 58 (03) : 623 - 632

← 1 2 3 4 5 →